Dr Reddy's Laboratories today said it has launched Repatha, a cholesterol lowering drug, in the country after getting approval from the health regulator.
The company launched Repatha in the country, the first and only PCSK9 inhibitor, approved by the Drug Controller General India (DCGI), Dr Reddy's Laboratories said in a statement.
Repatha (evolocumab) is a patented product of Amgen global, indicated for the treatment of adult patients with primary hypercholesterolaemia or mixed dyslipidaemia.
The product would be manufactured by Amgen and distributed by the Hyderabad-based firm in the country.
Repatha is used as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients who are unable to reach LDL-C goals with the maximum tolerated dose of a statin.
"The launch of Repatha is another significant addition to Dr Reddy's cardiovascular portfolio, which we believe will provide a unique treatment option to patients in India who are at risk of heart attack, stroke and coronary problems," Dr Reddy's CEO, Branded Markets (India and Emerging Markets) M V Ramana said.
Shares of Dr Reddy's today ended 0.32 per cent up at Rs 2,241.05 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
